产业资助与核心结局指标集使用增加相关
该观察性综述基于WHO-ICTRP注册平台数据评估类风湿关节炎核心结局指标集(RA-COS)的使用情况,共纳入341项符合评价条件的试验。2019年前十年间基于发表结果的 uptake 维持在略高于80%,非商业资助试验计划测量RA-COS的可能性显著低于产业资助试验(60% vs 80%;校正OR 0.18,95%CI 0.11至0.32;P<0.001)。
要点
- 基于WHO-ICTRP可识别地域多样的大范围试验用于评价COS使用情况
- 2019年前十年基于发表结果的RA-COS使用率维持在略高于80%
- 非商业资助试验计划测量RA-COS的比例为60%,产业资助试验为80%
核心结论
- 产业资助与试验计划使用RA-COS的可能性增加相关,非商业资助试验计划测量RA-COS的可能性显著低于产业资助试验(校正OR 0.18,95%CI 0.11至0.32;P<0.001)。
研究设计与样本
- 观察性综述,对WHO-ICTRP注册平台索引的全部类风湿关节炎临床试验进行评价,共341项试验符合RA-COS使用评价条件。
主要发现
- 2019年前十年间基于发表结果的RA-COS使用评价维持在略高于80%。
- 非商业资助试验计划测量RA-COS的比例为60%,产业资助试验为80%(校正OR 0.18,95%CI 0.11至0.32;P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The objective of this study was to assess the uptake of the rheumatoid arthritis core outcome set (RA-COS) using data from multiple data providers, and to investigate factors that may influence this uptake. STUDY DESIGN AND SETTING: An observational review was carried out on all clinical trials of rheumatoid arthritis that were indexed on the World Health Organization-International Clinical Trials Registry Platform (WHO-ICTRP). Various measures of COS uptake were calculated from information presented in the trial registries and trial publications. Logistic regression was conducted to investigate factors thought to be associated with planned COS uptake. RESULTS: A total of 341 trials were eligible for the evaluation of RA-COS uptake. In the decade leading up to 2019, the assessment of uptake based on published results was maintained at just over 80%. Trials that were not commercially funded were much less likely to plan to measure the RA-COS than those with industry funding (60% vs. 80%; adjusted OR 0.18, 95% CI 0.11 to 0.32; P < 0.001). CONCLUSION: This study has demonstrated that the use of the WHO-ICTRP can identify a large and geographically diverse range of trials to include in the evaluation of COS uptake.
引用
- Kirkham JJ, Bracken M, Hind L, et al. Industry funding was associated with increased use of core outcome sets. J Clin Epidemiol. 2019. PMID: 31326541. doi:10.1016/j.jclinepi.2019.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。